Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease

Summary by The Manila Times
WILMETTE, Ill., May 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ('Monopar” or the 'Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing...

3 Articles

The Manila TimesThe Manila Times
Reposted by
Carroll County Mirror-DemocratCarroll County Mirror-Democrat
Lean Right

Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease

WILMETTE, Ill., May 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ('Monopar” or the 'Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing...

·Manila, Philippines (the)
Read Full Article
stocktitan.netstocktitan.net

Drug trial helps Wilson disease patients shed excess copper

Phase 2 data in nine Wilson disease patients show ALXN1840 sustainably lowers daily copper balance by boosting fecal excretion after years on standard care.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Right
100% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Carroll County Mirror-Democrat broke the news in Mount Carroll, United States on Tuesday, May 19, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

Wilmette icon

Wilmette

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal